Medicine details

Image Ezetim
Name Ezetim
Dosage Tablet
Generic Name Ezetimibe
Classes Metabolic Agent
Antihyperlipidemic/Lipid Lowering Agent
Diseases High Cholesterol
Metabolic Disorder
Company Incepta Pharmaceuticals Ltd.

Drug Package Details

Strength 10 mg
Storage Condition
Origin Country Bangladesh
Commercial Pack 30
Price per pack 300.00
Cost per pack 264.00
Package unit 10 tabs strip
Price per unit 10.00
Cost per unit 8.80
Discount 0
Coupon
Remarks

Ezetimibe

Ezetimibe is in a class of lipid-lowering compounds that selectively inhibits the intestinal absorption of cholesterol and related phytosterols. Ezetimibe reduces total-C, LDL-C, Apo B, and TG, and increases HDL-C in patients with hypercholesterolemia.

 

Ezetimibe is indicated for Primary Hypercholesterolemia and Hyperlipidemia (adjunct therapy with a statin).

  • The patient should be placed on a standard cholesterol-lowering diet before receiving Ezetimibe and should continue on this diet during treatment with Ezetimibe.
  • The recommended dose of Ezetimibe is 10 mg once daily. Ezetimibe can be administered with or without food.
  • Ezetimibe may be administered with an HMG-CoA reductase inhibitor (in patients with primary hypercholesterolemia) or with fenofibrate (in patients with mixed hyperlipidemia) for incremental effect.
  • For convenience, the daily dose of Ezetimibe may be taken at the same time as the HMG-CoA reductase inhibitor or fenofibrate, according to the dosing recommendations for the respective medications.

Side effects commonly associated with ezetimibe include-

  • Asthenia
  • Diarrhea
  • Cough
  • Back pain
  • Nasopharyngitis

 

  • Concurrent administration of Ezetimibe with a specific HMG-CoA reductase inhibitor or fenofibrate should be in accordance with the product labeling for that medication.
  • In post-marketing experience with Ezetimibe, cases of myopathy and rhabdomyolysis have been reported regardless of causality. Most patients who developed rhabdomyolysis were taking an HMG-CoA reductase inhibitor prior to initiating Ezetimibe.
  • Due to the unknown effects of the increased exposure to ezetimibe in patients with moderate or severe hepatic insufficiency, Ezetimibe is not recommended in these patients.
  • When ezetimibe is administered with an HMG-CoA reductase inhibitor in a woman of childbearing potential, refer to the pregnancy category and product labeling for the HMG-CoA reductase inhibitor.

Contraindication

Hypersensitivity to any component of this medication.

The combination of ezetimibe with an HMG-CoA reductase inhibitor is contraindicated in patients with active liver disease or unexplained persistent elevations in serum transaminases.